Page 42 - Roche Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nykode’s APC targeted vaccine technology can be delivered as mRNA and generate strong T cell responsesNykode’s APC targeted vaccine technology consistently results in faster, broader and stronger immune response compared to non-targeted vaccines, whether delivered as DNA or mRNA OSLO, Norway, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it is p

LEXINGTON, Mass., Oct. 6, 2023 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on...

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will present a corporate overview and participate in one-on-one investor meetings during the Jefferies 2023 CNS & Neuro Summit, taking place in-person in New York City on October 11-12, 2023. AC Immune’s cor

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the results of imaging analyses...

–– Late-breaking results from Phase III trial of Ocrevus subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis will be presented –– 10-year Ocrevus...